Protein discovery could treat obesity, diabetes

Researchers, led by Suresh Alahari, PhD, Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, have brought the fight against obesity and diabetes to the cellular level with a study outlining the potential of the Nischarin protein.

Published in the Journal of Biological Chemistry, the study found the Nischarin protein was able to change metabolism in mice. Previous research found the protein acted as a tumor suppressor. Researchers further evaluated Nischarin's effects when interacting with the AMPK gene responsible for metabolic stability.

When bound to AMPK, Nischarin inhibits its activity and led to a decrease in the activation of genes in charge of producing glucose. Nischarin also interacted with the gene for regulating glucose uptake, lowering the level of blood glucose levels in mice and improving glucose and insulin tolerance. Genes involved in fat metabolism and the buildup of fat were also affected, giving the mice an increase in energy and appetite suppression. These factors combined led to a decrease in food intake and weight reduction in mice.

"These studies demonstrate the potential of Nischarin as a regulator of metabolic diseases and suggest suppression of Nischarin function may be a valuable approach in the quest to cure such diseases as diabetes and obesity," wrote Alahari.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.